Advances in technology have made it possible to deliver a high Kt/V in a shorter time. The realization that duration of dialysis may be an important predictor of survival independent of dialysis dose has resulted in the popularity of prolonged slow dialysis (PHD). The longer duration and increased frequency of dialysis achieve excellent small- and middle-molecular weight solute clearance and also attenuate the peak concentration of uremic toxins. The slow dialysis process enables the equilibration of tissue and vascular compartments, resulting in better clearance and decreased postdialysis rebound increase in solutes. Gentle, persistent ultrafiltration allows the control of hypertension with minimal antihypertensive use. The intense and more frequent dialysis improves appetite and permits liberalization of diet. This greater dietary protein intake results in a progressive increase in serum albumin level and dry weight. Nocturnal hemodialysis achieves control of hyperphosphatemia without phosphate binders and a significant reduction in serum beta(2)-microglobulin levels. Normalization of extracellular volume, better clearance of uremic toxins, and improved nutrition result in a significant improvement in survival. The flexible time schedule with home hemodialysis and improvement of sleep and neurocognitive function allow better rehabilitation. The available evidence indicates PHD may be closer to the concept of an ideal dialysis, but there is lingering uncertainty about the consequence of prolonged immune stimulation, catabolism, and loss of essential solutes with these therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0272-6386(99)70382-3DOI Listing

Publication Analysis

Top Keywords

dialysis
8
frequent dialysis
8
slow dialysis
8
uremic toxins
8
better clearance
8
search ideal
4
ideal hemodialysis
4
hemodialysis prolonged
4
prolonged frequent
4
dialysis answer?
4

Similar Publications

Introduction: Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD), enhancing survival and quality of life. However, kidney transplant recipients (KTRs) are at high risk for bone disorders, particularly low bone turnover disease, which increases fracture risk. Teriparatide, an anabolic agent, may provide a beneficial treatment option for these patients.

View Article and Find Full Text PDF

Contrast media are essential agents that enhance the diagnostic capabilities of imaging studies, such as computed tomography and magnetic resonance imaging. However, concerns regarding the risk of adverse events have led to cautious use in patients with chronic kidney disease. A multidisciplinary review by nephrologists, cardiologists, and radiologists at National Taiwan University Hospital examined evidence linking iodinated contrast media and gadolinium-based contrast agents with acute kidney injury and nephrogenic systemic fibrosis.

View Article and Find Full Text PDF

Unexpected finding of encapsulating peritoneal sclerosis: mind the cocoon.

BMJ Case Rep

January 2025

Nephrology and Transplantation, Erasmus MC, Rotterdam, The Netherlands

Here, we present a fatal case of a man in his 40s with encapsulating peritoneal sclerosis (EPS). In retrospect, a spot diagnosis on the abdominal CT scan. The patient presented with progressive abdominal complaints of pain and vomiting over the last 2 months.

View Article and Find Full Text PDF

Combination of clinical frailty score and myostatin concentrations as mortality predictor in hemodialysis patients.

J Ren Nutr

January 2025

Departments of Nephrology - Dialysis - Transplantation, University of Liege, CHU de Liège, Liège, Belgium; Nephrology, Dialysis, Apheresis Unit, Centre Hospitalier Universitaire Caremeau, Nimes, University of Montpellier, Montpellier, France.

Background And Aims: Frailty is common among hemodialysis (HD) patients. Its assessment is usually based on clinical criteria. In the present work, we evaluated the interest of combining clinical frailty score and biomarkers to predict mortality of chronic HD patients.

View Article and Find Full Text PDF

A Population Pharmacokinetic Analysis to Evaluate the Impact of Renal Impairment on the Pharmacokinetics of Iberdomide.

J Pharm Sci

January 2025

Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.

Iberdomide, a novel potent cereblon E3 ligase modulator, is under investigation for multiple myeloma. This study assessed how renal impairment (RI) affects iberdomide pharmacokinetics (PK). Twenty-six subjects with varying renal function, including those with severe renal impairment and those requiring intermittent hemodialysis (IHD), received a single oral 1 mg dose of iberdomide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!